Abstract |
The aim of this work was to compare the recurrence of diverticulitis during a 5-year follow-up in a population of patients affected by symptomatic uncomplicated diverticular disease (SUDD), taking either 800 mg of mesalamine b.i.d for 10 days every month or no 5-ASA. Sixty-seven consecutive patients affected by SUDD followed-up every 6 months for 5 years. All patients in this group (M-group) were requested to consume mesalamine 800 mg b.i.d for 10 days every month. A control group (C-group) of 82 subjects with SUDD allocated in an institution for the elderly and taking no 5-ASA medications was also followed-up for the same period. As a result in the M-group 14.9% of patients did not complete the follow-up, and diverticulitis developed in two patients (4%; 95% CI 1.1-13.5). In the C-group 6.1% patients did not complete the follow-up, and diverticulitis developed in 8 patients (10.4%; 95% CI 5.4-19.2). The difference between the two groups was not significant (difference = -6.4%; 95% CI -15.6 to 4.3; log rank test: p = 0.1256). Cyclic treatment with mesalazine seems to be clinical, although not statistically effective in reducing the incidence of diverticulitis. In future well-designed RCTs are necessary to demonstrate the therapeutic gain of the use of mesalazine, if any, in the management of patients with SUDD.
|
Authors | Luigi Gatta, Francesco Di Mario, Margherita Curlo, Dino Vaira, Alberto Pilotto, Paolo Lucarini, Maurizio Lera, Kajo Enkleda, Angelo Franzé, Carmelo Scarpignato |
Journal | Internal and emergency medicine
(Intern Emerg Med)
Vol. 7
Issue 2
Pg. 133-7
(Apr 2012)
ISSN: 1970-9366 [Electronic] Italy |
PMID | 21279478
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Mesalamine
|
Topics |
- Administration, Oral
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(adverse effects, therapeutic use)
- Biopsy, Needle
- Confidence Intervals
- Diverticulitis, Colonic
(drug therapy, mortality, prevention & control)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Long-Term Care
- Male
- Mesalamine
(adverse effects, therapeutic use)
- Middle Aged
- Prospective Studies
- Risk Assessment
- Secondary Prevention
- Severity of Illness Index
- Statistics, Nonparametric
- Survival Rate
- Treatment Outcome
|